for people ages 18 years and up (full criteria)
at La Jolla, California and other locations
study started
estimated completion
Principal Investigator
by Rafael Bejar, MD
Photo of Rafael Bejar
Rafael Bejar



The purpose of this study is to collect information and bone marrow, blood, saliva, cheek cells and skin to be used in the laboratory to assist the sponsor in identifying a new way of treating MDS.

Official Title

Collection of Bone Marrow, Peripheral Blood (PB), Epithelial Tissue, and Saliva Samples From Patients With Myelodysplastic Syndromes (MDS) to Identify MDS-Specific Antigens (MSA) for Use in Cellular Immunotherapy.


Goals of the study: The purpose of this study is to collect the blood and marrow samples, and non-involved fibroblasts, that are required to identify the unique, personalized array of mutation-driven neoantigens that are expressed by the subject's MDS cells and to assess the feasibility of immunizing and expanding one or more of the patient's T cells ex vivo for investigation of their use as adoptive cellular immunotherapy.


Myelodysplastic Syndromes(MDS) Preleukemia Myelodysplastic Syndromes Syndrome


For people ages 18 years and up

Patients must meet the following initial inclusion criteria:

  • Diagnosis or suspected diagnosis of MDS or CCUS
  • Age 18 or older

Patient exclusion criteria:

  • Currently receiving or within 3 months has received hypomethylating agent(s), lenalidomide, cytotoxic agents, or within the previous 4 weeks corticosteroids > 5 mg prednisone daily or any other immunosuppressants
  • Previous allogenic transplant
  • Inability to provide consent
  • Prisoners


  • University of California San Diego accepting new patients
    La Jolla California 92093 United States
  • University of California, Irvine accepting new patients
    Irvine California 92868 United States

Lead Scientist at UCSD

  • Rafael Bejar, MD
    Our lab is focused on understanding the genetic changes that drive the development and progression of hematologic malignancies like acute myeloid leukemia and myelodysplastic syndromes. Our goal is to translate our discoveries into clinically meaningful improvements in how we care for patients with these disorders.


accepting new patients
Start Date
Completion Date
PersImmune, Inc
Study Type
Last Updated